scPharmaceuticals Q2 2025 Earnings Call Highlights Growth

Scpharmaceuticals ((SCPH)) has held its Q2 earnings call. Read on for the main highlights of the call.

The recent earnings call for scPharmaceuticals painted a generally positive picture, driven by significant revenue growth and successful product launches in the nephrology and IDN segments. Despite facing challenges such as increased gross to net discounts and declining cash reserves, the company’s strategic advancements and achievements suggest an optimistic outlook.

Significant Revenue Growth

In the second quarter of 2025, scPharmaceuticals reported net revenue of $16 million, marking an impressive 99% increase over the same period in 2024. This substantial growth underscores the company’s successful strategies and market penetration efforts.

Increase in FUROSCIX Doses

The company filled approximately 20,200 FUROSCIX doses in Q2 2025, representing a 117% increase over Q2 2024 and a 45% increase over Q1 2025. This surge in demand highlights the growing acceptance and success of FUROSCIX in the market.

Nephrology Launch Success

The nephrology segment showed strong enthusiasm for FUROSCIX, with nephrologists adopting the product faster than cardiologists initially did. This rapid uptake is expected to contribute significantly to the company’s performance in the third quarter.

IDN Distribution Strategy

The IDN business exceeded expectations, achieving a 70% growth quarter-over-quarter. This performance highlights the effectiveness of scPharmaceuticals’ distribution strategy and its ability to surpass internal growth forecasts.

Auto-Injector SNDA Submission

scPharmaceuticals is on track to submit a supplemental new drug application for an auto-injector, which is anticipated to reduce the cost of goods sold by approximately 75%. This development is expected to enhance market penetration and drive future growth.

Increased Gross to Net Discount

The gross to net discount for FUROSCIX in Q2 2025 was approximately 27%, with expectations to approach 30% in Q3 due to the Medicare Part D redesign. This increase poses a challenge but is part of the broader strategic adjustments in the market.

Cash Decline

Cash and cash equivalents fell to $40.8 million as of June 30, 2025, from $75.5 million at the end of 2024. This decline reflects the company’s investment in growth and strategic initiatives, though it highlights the need for careful financial management moving forward.

Forward-Looking Guidance

Looking ahead, scPharmaceuticals anticipates continued revenue growth, driven by the strong uptake of FUROSCIX and strategic market positioning. The company expects quarterly net cash flows to decrease as revenues increase, and it remains on track to submit a supplemental new drug application for an auto-injector, which is expected to significantly reduce costs and boost growth.

In summary, scPharmaceuticals’ earnings call conveyed a positive sentiment, with notable achievements in revenue growth and product launches. While challenges such as increased discounts and cash declines were acknowledged, the company’s strategic initiatives and forward-looking guidance suggest a promising future.